论文部分内容阅读
为了解肺心病患者血栓烷Ａ２（ＴＸＡ２）及前列环素（ＰＧＩ２）的含量变化，分别对２８例肺心病缓解期患者、２９例急性发作期患者治疗前后及１０例健康人进行了ＴＸＢ２和６－ｋｅｔｏ－ＰＧＦ１α的含量测定。结果：健康人组血浆ＴＸＢ２和６－ｋｅｔｏ－ＰＧＦ１α的含量分别为１０９．７４±５６．１４ｎｇ／Ｌ及５４．７６±３５．６２ｎｇ／Ｌ，ＴＸＢ２／６－ｋｅｔｏ－ＰＧＦ１α＝２．００４。肺心病各期患者ＴＸＢ２含量均明显高于正常人（Ｐ＜０．０５～０．０１），其中以急性发作期最高（７０９．２２±３５４．４９ｎｇ／Ｌ），经中西医结合治疗后下降为４０８．２４±２８９．４１ｎｇ／Ｌ（Ｐ＜０．０５），与缓解期含量３３３．４±３２４．１４ｎｇ／Ｌ无显著差异（Ｐ＞０．０５）。但肺心病各期患者６－ｋｅｔｏ－ＰＧＦ１α与健康组相比均无显著差异。由于ＴＸＢ２增高，致ＴＸＢ２／６－ｋｅｔｏ－ＰＧＦ１α均明显高于健康组
In order to understand the changes of thromboxane A2 (TXA2) and prostacyclin (PGI2) in patients with cor pulmonale, the levels of TXB2 and 6 in 28 patients with remission of pulmonary heart disease, 29 patients with acute exacerbation before and after treatment and 10 healthy people -keto-PGF1α content determination. Results: The levels of TXB2 and 6-keto-PGF1α in healthy volunteers were 109.74 ± 56.14ng / L and 54.76 ± 35.62ng / L, respectively, and TXB2 / 6-keto-PGF1α = 2.004. The levels of TXB2 in all stages of pulmonary heart disease were significantly higher than those in normal subjects (P <0.05 ~ 0.01), with the highest in acute stage (709.22 ± 354.49 ng / L) Which was 408.24 ± 289.41ng / L (P <0.05), but no significant difference with 333.4 ± 324.14ng / L in remission (P> 0.05). However, there was no significant difference between 6-keto-PGF1α and healthy group in all stages of pulmonary heart disease. Due to the increase of TXB2, TXB2 / 6-keto-PGF1α was significantly higher than that of healthy group